Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amphastar Pharmaceuticals, Inc. - Common Stock
(NQ:
AMPH
)
18.41
+0.25 (+1.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amphastar Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023
November 01, 2023
Via
ACCESSWIRE
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
↗
October 31, 2023
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
↗
October 16, 2023
Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
↗
September 27, 2023
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.
Via
Investor's Business Daily
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
September 13, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
August 08, 2023
Via
ACCESSWIRE
Amphastar Pharma: Q1 Earnings Insights
↗
May 09, 2023
Via
Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
May 09, 2023
Via
ACCESSWIRE
Earnings Outlook For Amphastar Pharma
↗
May 08, 2023
Via
Benzinga
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
September 12, 2023
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 11, 2023
Via
Benzinga
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
September 11, 2023
Via
ACCESSWIRE
Lilly to Divest BAQSIMI to Amphastar
April 24, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
August 31, 2023
Via
ACCESSWIRE
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
↗
August 17, 2023
Eli Lilly and Company (LLY) boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer.
Via
Talk Markets
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
August 02, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
June 30, 2023
Via
ACCESSWIRE
Promising Small Biotech Amphastar Sees Actionable Pullback
June 28, 2023
Small-cap Amphastar Pharmaceuticals is pulling back from recent highs in an orderly fashion, potentially offering a new entry point after beating Q1 views.
Via
MarketBeat
Abcam Stock Earns Relative Strength Rating Upgrade
↗
June 20, 2023
A Relative Strength Rating upgrade for Abcam ADR shows improving technical performance.
Via
Investor's Business Daily
Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) Records 52-Week High Tuesday Morning
June 20, 2023
Via
Investor Brand Network
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
↗
June 06, 2023
On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier.
Via
Investor's Business Daily
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 31, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
May 03, 2023
Via
ACCESSWIRE
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
↗
May 03, 2023
On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday.
Via
Investor's Business Daily
Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash
↗
April 24, 2023
Via
Benzinga
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
April 24, 2023
Via
ACCESSWIRE
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
↗
April 17, 2023
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before.
Via
Investor's Business Daily
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
Via
ACCESSWIRE
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
↗
April 10, 2023
Via
Benzinga
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
↗
March 30, 2023
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier.
Via
Investor's Business Daily
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.